Invion announce a collaboration with 3M Drug Delivery Systems for the development of its inhaled respiratory drug franchise.
Invion’s agreement with 3M Drug Delivery Systems will assess the feasibility of inhaled versions of its two respiratory drug assets - INV102 (nadolol) and INV104 (zafirlukast) - delivered using 3M’s proprietary pressurized metered dose inhalation technology.
It will also enable manufacture for toxicology, and subsequently phase I studies, under an Invion-sponsored Investigational New Drug application, with the US Food and Drug Administration.
INV102 (nadolol) - a beta blocker currently used to treat high blood pressure and migraine, which is being repurposed by Invion to treat chronic inflammatory airway diseases, including moderate to severe asthma, COPD and cystic fibrosis.
INV104 (zafirlukast) - a leukotriene receptor antagonist (LTRA) which works by blocking the action of leukotrienes in the lungs, thereby preventing inflammation and narrowing of the airways.
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Report: Practical Guide to Finding Partners
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity